Onglyza Stacks Up To Januvia, Bristol/AstraZeneca Say
This article was originally published in Pharmaceutical Approvals Monthly
Onglyza efficacy is competitive with other DPP-4 inhibitors, Bristol-Myers Squibb/AstraZeneca say - Partners say new data on saxagliptin efficacy, presented at EASD in Rome, show competitive profile and are preparing a head-to-head trial with Merck's Januvia. Onglyza and Takeda's alogliptin could join Januvia on the market in the next year, but it's not clear how the new drugs will be differentiated. Heightened scrutiny of diabetes drug safety could help Merck maintain an advantage
You may also be interested in...
Despite downplaying any concern, Bristol-Myers Squibb is preparing for a potential challenge to its blockbuster anti-clotting drug Plavix from Lilly/Daiichi Sankyo's Effient (prasugrel)
Sponsors of new type 2 diabetes therapies should be required to provide clinical data that can exclude an unacceptable cardiovascular risk prior to approval, FDA's Endocrinologic and Metabolic Drugs Advisory Committee concluded at a July 1-2 meeting
With five Phase III wins for type 2 diabetes, company plans to build on Actos’ success.